MedTech Innovator

Qritive is a developer of an AI-powered diagnostic platform that assists medical professionals in analyzing microscopy images and patient data. The platform leverages artificial intelligence and natural language processing to streamline the analysis process, enhancing the efficiency of cancer diagnoses. By providing modern automated tools, Qritive aims to reduce the time and costs associated with cancer diagnosis, ultimately improving healthcare outcomes for patients. The company's innovative approach addresses the challenges faced by doctors in interpreting complex medical information, facilitating quicker and more accurate diagnoses.

Nurami Medical focuses on creating advanced surgical scaffolds aimed at enhancing the repair and regeneration of soft tissues following internal surgeries. Utilizing electrospinning technology, the company develops biomaterials and nanofiber-based matrices that improve patient outcomes in various surgical procedures. These matrices feature a porous scaffold that promotes tissue regeneration and incorporate a novel temperature-sensitive sealant designed to prevent pathogen entry and cerebrospinal fluid leaks. This innovative approach addresses critical needs in surgical treatment, providing surgeons with effective solutions for their patients.

3EO Health is focused on creating a society where individuals can take charge of their health, benefiting themselves, their families, and their communities. The company develops innovative molecular point-of-care platforms that utilize advanced technology to significantly reduce costs while enhancing access to impactful diagnostic tools. By offering 3TR technology, 3EO Health ensures that both physicians and consumers have equitable access to affordable and user-friendly health solutions. This approach aims to extend healthcare beyond traditional settings into communities, workplaces, and homes, empowering people to thrive and optimize their health effectively.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

CORIT Medical LLC is a commercial medical device company located in McLean, VA, with a specific focus on a Class I single-use surgical device to improve breathing. The established Ear, Nose & Throat (ENT) procedure is called inferior turbinate reduction and has an existing reimbursement code. There are currently 1 million procedures performed in the US each year, and reportedly over 50 million people who suffer from obstructed breathing. The patented CORIT device is hand-powered requiring no expensive equipment to set up and operate. It has also shown to produce more durable results in contrast with competing technologies that can return to pre-treatment baseline levels of obstruction in as few as six months. ENTs are lined up, ready to buy the device, as they can complete the procedure in in a fraction of the time, right in their office (as opposed to an operating room), yielding a higher reimbursement.

Travera, LLC is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in a unique measurement technology that utilizes the Suspended Microchannel Resonator (SMR), a MEMS device capable of detecting minute changes in the weight of individual cancer cells. This technology focuses on the Mass Accumulation Rate (MAR) biomarker, which indicates how cancer cells respond to various drugs within hours of exposure. By measuring these rapid changes, Travera enables oncologists to make informed decisions about which therapies to prescribe based on the actual responses of a patient’s tumor cells. This approach aims to enhance the effectiveness of cancer treatment by distinguishing between natural cell death and drug-induced cell death, thereby improving patient outcomes.

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients at home. The device employs a closed-loop approach and machine learning algorithms to deliver personalized peripheral neuromodulation therapy. This innovative technology mediates a cardiovascular antiarrhythmic response, helping users to alleviate the burden of atrial fibrillation and address precursors such as premature atrial contractions. As a result, CardiaCare’s device offers users the potential for rapid clinical and symptomatic relief.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape. Bardy Diagnostics uses his expertise to develop cardiac monitoring solutions that help physicians obtain more accurate information about actionable events in the hopes of saving lives. The company's mission is to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses. Bardy Diagnostics was founded in 2013 and is headquartered in Seattle, Washington, USA.

AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.

PhotoniCare, Inc. is a medical device company based in Champaign, Illinois, founded in 2013. The company specializes in developing innovative diagnostic tools for middle ear infections, notably the TOMi Scope. This handheld device employs advanced light-based technology, specifically near-infrared light waves, to create 3D images of the middle ear by seeing through the eardrum. This capability allows physicians to visualize the middle ear directly and safely, enabling them to assess its condition quickly and accurately. By determining the contents of the middle ear, clinicians can make informed decisions regarding the need for antibiotics or surgical interventions. PhotoniCare's technology not only addresses otology but also presents potential for growth in other medical fields.

AuriGen Medical Limited is an electrophysiology and structural heart company based in Dublin, Ireland, founded in 2016. The company focuses on developing innovative left atrial appendage (LAA) implants designed to address the stroke and arrhythmia risks associated with persistent atrial fibrillation (AF). AuriGen's technology targets highly symptomatic patients who are resistant to medication, a demographic that includes over 3 million individuals in the United States and Europe. The rising incidence of AF, particularly among aging populations, underscores the urgent need for effective treatment alternatives. AuriGen's devices incorporate custom LAA occluder implants and are designed to enhance patient outcomes by reducing reliance on anticoagulants and anti-arrhythmic medications. With the annual costs of managing medication-resistant AF running into billions, AuriGen aims to provide cost-effective solutions that improve treatment efficacy and patient quality of life.

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

VADovations, Inc. is an Oklahoma City-based company specializing in the design and manufacture of advanced healthcare equipment, particularly focusing on miniaturized ventricular assist devices (VADs) for patients with end-stage heart failure. Founded in 2009, VADovations is developing a smaller and lighter mechanical blood pump that allows for less invasive surgical implantation, significantly reducing hospitalization times from three weeks to four days. The device is designed for percutaneous delivery and endovascular deployment, minimizing the risk of adverse events such as stroke, bleeding, thrombosis, and infection. By addressing the limitations of existing blood pumps, VADovations aims to enhance the capabilities of cardiothoracic surgeons and interventional cardiologists in providing circulatory support for patients in critical need.

Patientory, Inc. is a healthcare technology company based in Atlanta, Georgia, established in 2015. It offers a health data management platform that enables individuals to securely store, manage, and share their health information. The platform empowers patients to take control of their medical records and chronic illness management while facilitating better communication and support between healthcare providers and patients. By integrating a blockchain-enabled network, Patientory streamlines access to health data, enhances care coordination, and provides insights into health outcomes. This approach aims to democratize health data ownership, reduce healthcare costs, and improve overall patient engagement and health management.

Linear Health Sciences is a medical device company focused on developing innovative products for medical tubing, utilizing its proprietary breakaway safety-valve technology. This technology aims to prevent unwanted disconnection of medical tubing, thereby enhancing the healthcare experience for patients, caregivers, and healthcare facilities. The company has made significant strides in securing global patent protections and obtaining FDA clearance for its flagship product, the Orchid Safety Release Valve. With a total addressable market exceeding $1 billion annually, Linear Health Sciences was founded by a physician and two engineers, emphasizing a strong blend of medical and engineering expertise in its product development efforts.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, specializing in sequencing-based clinical microbiome tests. Founded in 2012, it offered a range of products including SmartGut, a test for identifying harmful and beneficial microorganisms linked to specific infections; SmartJane, a women’s health screening for conditions like HPV and STIs; Explorer kits for researchers and citizen scientists; and SmartFlu, a clinical test for respiratory infections. The company's goal was to enhance understanding of the human microbiome and its implications for health. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019, marking the end of its operations.

AventaMed is a start-up medical device company focused on improving patient care and reducing healthcare costs. The company is a spin-out from the 'MEDIC' research centre within the Cork Institute of Technology and has been founded upon technology developed from 4 years of product development.